John Parkinson

Ferring’s Rebyota, which was FDA approved late last year, demonstrated a high efficacy and favorable safety profile in the prevention of recurrent Clostridioides difficile.

The Committee for Medicinal Products for Human Use expressed a positive opinion for bulevirtide for treatment of hepatitis D (HDV).

Carlos Del Rio, MD, updates clinicians and the public on where we are now on the respiratory virus and the modalities to treat and prevent severe disease.

A clinician provides insights on this significant topic as well as resources in finding information on them.

A clinician offers some insights and considerations on clinical care as it pertains to climate.

The Gates Medical Research Institute (MRI) is collaborating with Atreca on an investigational therapy, MAM01, which is moving into clinic trials this year.

Members of both branches brought it back to gain support and passage of a bill aimed at greater development of antibiotics.

A clinician offers ideas about who to target for immunization and strategic considerations when having these conversations.

One of the most challenging aspects of clinicans’ jobs is giving patients and staff bad news. A clinician offers some strategies to help shape an approach in having these conversations.

Artificial intelligence (AI) is being utilized already says one clinician. She explains her optimism about the technology, and says it will help augment any potential challenges providers have now or in the future.

A paradigm shift is emerging when it comes to the clinical approach to prescribing antibiotics. One clinician weighs in on using this class of therapeutics more judiciously.

An epidemiologist offers some insights on what we need to take into a potential next pandemic including infrastructure investment and more effectively communicating messages to the public.

This gathering is the nation’s largest for internal medicine doctors and has many infectious disease-related scientific sessions.

The antiviral is being studied for treatment for those at high-risk for severe COVID-19, no matter their vaccine status.

The Peggy Lillis Foundation will host its summit on Monday and has a number of speakers who will discuss topics related to this healthcare-associated infection (HAI).

A key stakeholder offers his insights on the importance of the new Biden plan to eliminate hepatitis C as well as the federal strategy to get more people linkage to care for hepatitis B.

The FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) voted 12-0 in favor of recommending this antibiotic and sets up a PDUFA target action date of May 29.

Since the lifting of public health restrictions, the country saw a sizable increase in incidence rates.

With an FDA approval, it would be the first new class of oral antibiotics for uncomplicated urinary tract infections (uUTI) in over 20 years.

Several years after its FDA approval, this antibiotic continues to prove its efficacy in vitro across various pathogens related to these infections.

A new study presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) examined a rapid cellular host response test designed to aid providers who are working in emergency departments and need quick, efficient diagnostic information.

People with COVID-19 who were hospitalized had a slightly higher rate of death than those with influenza. However, there were considerably more severe COVID-19 cases than the flu, leading to a much higher number of overall deaths associated with SARS-CoV-2.

With limited amounts of antibacterials, prescribers are presented with optimal therapy challenges as well as difficulties in trying to achieve stewardship.

The R21/Matrix-M vaccine can now be used in Ghana and could help in the prevention of a vector-borne disease that kills over 600,000 people annually.

The Veterans Administration reported a reduction in the bacterial infection in healthcare settings where infection prevention practices were continued.

The epidemiology society worked with a few medical organizations to update the guidance to limit infections.

A study looking at 5 years of data showed a decrease in the amount of cases, but with some important trends to be aware of in this population.

The US Department of Agriculture’s Food Safety and Inspection Service (FSIS) issues public health alert for salad with chicken and ham.

In patients with hepatitis D (HDV) and compensated cirrhosis, a newer antiviral therapy, bulevirtide (Hepcludex), proved to be efficacious and safe to patients.

When taken within 3 days, doxycycline given post-exposure (doxy-PEP) decreased the incidence rates of syphilis, gonorrhea, and chlamydia significantly.